Navigation Links
Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations
Date:11/4/2008

ared to $12.3 million or $0.83 per share on a diluted basis for the same period in 2007. Net income for the nine month period ended Sept. 30, 2007 includes a charge for the write-off of deferred financing costs related to the Company's term debt, which was paid off in the third quarter of 2007 in the amount of $4.2 million or $0.18 per diluted share. Excluding the effect of this item, earnings per share for the nine months ended Sept. 30, 2007 were $1.01 on a diluted basis.

Net service revenues for the nine-month period ended Sept. 30, 2008, were $365.9 million, an increase of 25 percent over net service revenues of $293.3 million for the same period in 2007. Net service revenues from DecisionLine Clinical Research Corporation accounted for approximately 3 percent of the growth in net service revenues.

Income from operations for the nine-month period ended Sept. 30, 2008, was $45.9 million, or 12.5 percent of net service revenues, compared to income from operations of $37.6 million, or 12.8 percent of net service revenues for the same period of the prior year.

Cash flow from operations for the first nine months of 2008 totaled $3.4 million compared with $38.1 million for the same period last year. Capital expenditures for the first nine months of 2008 totaled $18.1 million compared to $10.8 million for the same period in the prior year.

Updated Full-Year Guidance

For the full year 2008, Kendle is now projecting net service revenues in the range of $485 million to $500 million, earnings per share on a diluted basis of $2.10 to $2.25 and operating margin between 12.5 and 13.5 percent. Kendle previously had projected net service revenues in the range of $490 million to $500 million, earnings per share on a diluted basis of $2.00 to $2.15 and operating margin between 13 and 14 percent.

Third Quarter 2008 Conference Call and Webcast Details

Kendle will host its Third Quarter 2008 conference call Nov. 5, 2008, at 8:30 a.m.
'/>"/>

SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Kendle Named to FORTUNE List of 100 Fastest-Growing Companies for 2008
2. Kendle to Present at the UBS Global Life Sciences Conference
3. Kendle Invites You to Attend its Second Quarter 2008 Earnings Conference Call and Webcast
4. Kendle to Host Conference Call and Webcast to Discuss DecisionLine Acquisition and Provide Update on Second Quarter Progress
5. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
6. Kendle Appoints Patricia Williams Vice President, Commercial Operations
7. Kendle Invites You to Attend its First Quarter 2008 Earnings Conference Call and Webcast
8. Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
9. Kendle Leaders Adopt 10b5-1 Trading Plans
10. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
11. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
(Date:7/30/2015)... customers across the globe, ISN improves the efficiency and effectiveness of contractor management systems. ... and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Headquartered in Dallas, TX , ISN has additional offices in ...
(Date:7/30/2015)... July 30, 2015 HIGHLIGHTS:Q2 2015 ... 2014) , Reported sales were $697 million compared ... Sales grew organically by 8%, and changes in foreign ... increased sales by 1%. , By business unit, ... Applied and 11% in SAFC Commercial. , Reported ...
(Date:7/30/2015)... ... July 30, 2015 , ... As part of its 2015 growth plan and as ... technical service business units, Whitehouse Laboratories is pleased to announce that it has ... the Container Center of Excellence and will be strictly dedicated to basic USP 51, USP ...
Breaking Biology Technology:Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... MOUNTAIN VIEW, Calif., Oct. 16 Based on ... in healthcare, Frost & Sullivan recognizes Agile Therapeutics, ... & Biotechnology Healthcare Innovation of the Year Award ... lead product, AG200-15 with SKINFUSION(TM), offers great potential ...
... 16 MGM Innova, LLC (MGM Innova) and MACTEC ... alliance in carbon management services. Marco G. Monroy, President ... of MACTEC Engineering and Consulting, Inc., made the joint ... become the leading provider of integrated solutions across the ...
... AUSTIN, TexasResearchers at The University of Texas at Austin have ... world,s smallest test tube, measuring a thousandth the diameter of ... small that a high-power electron microscope was required to see ... the test tube was stuffed with a thread-like crystal (a ...
Cached Biology Technology:Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch 2Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch 3Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch 4Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch 5MACTEC and MGM Innova Announce Strategic Alliance in Carbon Management Services 2Tiny test tube experiment shows reaction of melting materials at the nano scale 2
(Date:7/27/2015)... 27, 2015   Zynx Health ™, the ... improvement solutions, today announced that its ZynxCarebook ... on Android smartphones and tablets. With this expansion, ... can use ZynxCarebook to securely exchange messages and ... care transitions to other care settings, and improve ...
(Date:7/21/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market and ... it has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology ... but also the user using unique personal identifiers ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION ... new convenient and secure method to make payments.  ... payment methods, introduced with its groundbreaking voice-direct payment ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... of the University of Granada has found out ... the olive skin wax extracted from alpeorujo (crushed olive pulp), ... apoptosis in carcinogenic processes., Maslinic acid is a protease inhibitor ... growth. It is useful for cancer treatment, as it allows ...
... cigarette after a Valentines Day snuggle can prematurely end a ... in a gene significantly increases a smokers risk of an ... to 70 percent of the population has a gene defect ... recent published study, heavy smokers with this common gene variant ...
... Critically ill patients who need a ventilator to ... infection, however, is exceedingly difficult to diagnose because a ... masks pneumonia,s symptoms a reality that can delay ... at Washington University School of Medicine in St. Louis ...
Cached Biology News:A compound extracted from olives inhibits cancer cells growth and prevents their appearance 2Cigarette after Valentine snuggle deadlier for some 2Cigarette after Valentine snuggle deadlier for some 3Gene chips used to distinguish ventilator-associated pneumonia from underlying critical illness 2Gene chips used to distinguish ventilator-associated pneumonia from underlying critical illness 3Gene chips used to distinguish ventilator-associated pneumonia from underlying critical illness 4
... Ac-DEVD-CHO is an ... activity. The concentration of ... caspase activity must be ... system. Ten micromolar inhibitor ...
TUNEL Apoptosis Detection Kit...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
homeo box D3, mRNA...
Biology Products: